Jérôme Galon
#88,426
Most Influential Person Now
French biologist
Jérôme Galon's AcademicInfluence.com Rankings
Jérôme Galonbiology Degrees
Biology
#4653
World Rank
#6918
Historical Rank
Immunology
#206
World Rank
#215
Historical Rank
Download Badge
Biology
Jérôme Galon's Degrees
- PhD Immunology Université Paris Cité
- Doctorate Medicine Université Paris Cité
Why Is Jérôme Galon Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jérôme Galon is a French biologist. He is a first class Research Director at Institut National de la Santé et de la Recherche Médicale . Education Galon received his Ph.D. degree with a specialty in immunology in 1996 and did postdoctoral work at the National Institute of Health , in Bethesda between 1997 and 2001. Since 2001, he has been working at the Cordeliers Research Center, where he has been the Director of the INSERM Laboratory Integrative Cancer Immunology since 2009.
Jérôme Galon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (2006) (5550)
- ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks (2009) (4533)
- The immune contexture in human tumours: impact on clinical outcome (2012) (3706)
- Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. (2013) (2351)
- Effector memory T cells, early metastasis, and survival in colorectal cancer. (2005) (1994)
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies (2019) (1488)
- Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes (1999) (1254)
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (2018) (1224)
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013) (1136)
- Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. (2011) (981)
- Immune infiltration in human tumors: a prognostic factor that should not be ignored (2010) (973)
- Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. (2011) (896)
- In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. (2009) (852)
- CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data (2013) (824)
- Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. (2016) (754)
- Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
- The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. (2013) (704)
- Consensus guidelines for the detection of immunogenic cell death (2014) (634)
- Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells (2002) (562)
- The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy (2020) (543)
- The immune score as a new possible approach for the classification of cancer (2012) (542)
- From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. (2013) (439)
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy (2015) (397)
- The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. (2007) (392)
- The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. (2000) (388)
- Prognostic and predictive impact of intra- and peritumoral immune infiltrates. (2011) (361)
- Classification of current anticancer immunotherapies (2014) (357)
- The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis (2016) (349)
- The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. (2001) (334)
- Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer (2014) (297)
- Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. (2010) (290)
- Evolution of Metastases in Space and Time under Immune Selection (2018) (282)
- Cancer immunology—analysis of host and tumor factors for personalized medicine (2011) (274)
- Tumor Immunology and Tumor Evolution: Intertwined Histories. (2020) (259)
- TNFRSF1A mutations and autoinflammatory syndromes. (2000) (249)
- Coordination of intratumoral immune reaction and human colorectal cancer recurrence. (2009) (249)
- Implications of the tumor immune microenvironment for staging and therapeutics (2018) (243)
- Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes1 (2000) (243)
- From mice to humans: developments in cancer immunoediting. (2015) (223)
- Trial Watch—Oncolytic viruses and cancer therapy (2016) (221)
- Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases (2016) (215)
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy (2015) (207)
- Immune infiltration in human cancer: prognostic significance and disease control. (2011) (199)
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival (2018) (198)
- Stat4 Is Expressed in Activated Peripheral Blood Monocytes, Dendritic Cells, and Macrophages at Sites of Th1-Mediated Inflammation1 (2000) (198)
- The Immunoscore: Colon Cancer and Beyond (2019) (196)
- The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. (2018) (189)
- Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients (2014) (180)
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy (2012) (179)
- Tumor immunosurveillance in human cancers (2011) (177)
- Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. (2015) (176)
- Trial watch (2013) (176)
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) (175)
- Immune evasion before tumour invasion in early lung squamous carcinogenesis (2019) (172)
- Natural immunity to cancer in humans. (2010) (171)
- Trial Watch: Monoclonal antibodies in cancer therapy (2012) (167)
- Positive Effects of Glucocorticoids on T Cell Function by Up-Regulation of IL-7 Receptor α1 (2002) (163)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Trial watch (2013) (148)
- Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. (2016) (143)
- T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. (2016) (135)
- Glucocorticoids and Inflammation Revisited: The State of the Art (2003) (126)
- Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 (2016) (125)
- Trial watch (2012) (124)
- The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact (2013) (123)
- Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. (1996) (116)
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment (2013) (113)
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications (2015) (111)
- Trial watch (2012) (110)
- The essential role of the in situ immune reaction in human colorectal cancer (2008) (107)
- IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. (1999) (106)
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy (2016) (103)
- The prognostic impact of anti-cancer immune response: a novel classification of cancer patients (2011) (103)
- Trial Watch: Peptide-based anticancer vaccines (2015) (102)
- Trial Watch (2013) (101)
- Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer (2020) (87)
- Trial Watch (2012) (86)
- Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment (2018) (85)
- Trial Watch (2013) (83)
- Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. (2016) (80)
- Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. (2020) (79)
- Trial Watch (2012) (79)
- Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. (2020) (79)
- Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy (2014) (72)
- Trial Watch (2014) (72)
- Trial watch: Dendritic cell-based anticancer therapy (2014) (70)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- The immune landscape of human tumors (2014) (66)
- Comprehensive functional analysis of large lists of genes and proteins. (2018) (66)
- Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure (2006) (63)
- Germline genetic contribution to the immune landscape of cancer (2020) (61)
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications (2016) (60)
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (57)
- Toward integrative cancer immunotherapy: targeting the tumor microenvironment (2012) (56)
- Trial watch (2012) (56)
- Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer (2022) (55)
- Adrenal cortical activation in murine colitis. (2000) (54)
- Immunosurveillance in human non-viral cancers. (2011) (54)
- Trial Watch (2012) (51)
- Trial Watch: Radioimmunotherapy for oncological indications (2014) (50)
- Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. (2015) (50)
- Soluble FCγ receptors (1993) (49)
- Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy (2016) (49)
- Trial Watch: Lenalidomide-based immunochemotherapy (2013) (49)
- Hierarchy of Protein Tyrosine Kinases in Interleukin-2 (IL-2) Signaling: Activation of Syk Depends on Jak3; However, Neither Syk nor Lck Is Required for IL-2-Mediated STAT Activation (2000) (48)
- Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity (2002) (47)
- Trial watch (2005) (45)
- Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response (2020) (45)
- Trial Watch—Immunostimulation with cytokines in cancer therapy (2016) (44)
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications (2015) (44)
- Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16) (1998) (44)
- Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses. (1993) (43)
- A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy (2020) (43)
- Automated exploration of gene ontology term and pathway networks with ClueGO-REST (2019) (43)
- Affinity of the interaction between Fcgamma receptor type III (FcγRIII) and monomeric human IgG subclasses. Role of FcγRIII glycosylation (1997) (43)
- A New Set of Monoclonal Antibodies Against Human FcγRII (CD32) and FcγRIII (CD16): Characterization and Use in Various Assays (1997) (42)
- Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. (1999) (42)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
- Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). (2017) (41)
- Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion (2021) (41)
- Trial Watch (2014) (41)
- TGF-beta does not inhibit IL-12- and IL-2-induced activation of Janus kinases and STATs. (1999) (41)
- Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies (2015) (39)
- Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer (2020) (39)
- Immunoscore and its introduction in clinical practice. (2020) (39)
- Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-11 (2001) (39)
- Bioinformatics for cancer immunology and immunotherapy (2012) (38)
- Do glucocorticoids participate in thymocyte development? (2000) (38)
- Trial Watch (2012) (37)
- Trial Watch (2014) (37)
- Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells (2002) (36)
- T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. (2016) (33)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
- Trial Watch: Adoptive cell transfer for oncological indications (2015) (32)
- Frameshift mutations, neoantigens and tumor-specific CD8+ T cells in microsatellite unstable colorectal cancers (2016) (32)
- Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer (2020) (31)
- Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone in human cells. (2001) (31)
- Trial Watch (2013) (31)
- Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. (2005) (30)
- Erratum: T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells (Cancer Cell (2016) 30(3) (377–390)(S1535610816303890)(10.1016/j.ccell.2016.08.004)) (2016) (30)
- Trial watch (2013) (29)
- An alternative Fc gamma-receptor ligand: potential role in T-cell development. (1994) (29)
- Trial Watch (2014) (29)
- Trial watch: Naked and vectored DNA-based anticancer vaccines (2015) (29)
- Soluble CD16/Fc gamma RIII induces maturation of dendritic cells and production of several cytokines including IL-12. (1997) (28)
- Trial watch (2005) (28)
- Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. (2022) (27)
- Affinity of the interaction between Fc gamma receptor type III (Fc gammaRIII) and monomeric human IgG subclasses. Role of Fc gammaRIII glycosylation. (1997) (26)
- World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016 (2017) (26)
- Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction (2010) (25)
- Trial watch (2006) (24)
- Trial Watch (2004) (24)
- Regulation of CTL Infiltration Within the Tumor Microenvironment. (2017) (23)
- Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore (2020) (23)
- Soluble Fcγ Receptors: Interaction with Ligands and Biological Consequences (1997) (22)
- Ligands and biological activities of soluble Fcγ receptors (1995) (22)
- Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. (2002) (21)
- Microenvironnement immunitaire et cancer - Intérêt de l’immunoscore pour prédire l’évolution clinique (2014) (21)
- Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer (2020) (21)
- Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification. (2016) (21)
- The consensus immunoscore: toward a new classification of colorectal cancer (2020) (20)
- Presentation of Antigen in Immune Complexes Is Boosted by Soluble Bacterial Immunoglobulin Binding Proteins (1999) (19)
- Trial Watch (2013) (19)
- Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma (2022) (18)
- Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
- Trial watch (2005) (17)
- Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. (2019) (17)
- A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. (1997) (17)
- Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer (2020) (17)
- Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. (2010) (15)
- Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF). (2020) (15)
- Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ. (2020) (15)
- Not just another meeting: the coming of age of JAKs and STATs. (1998) (15)
- Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors (2021) (14)
- [Intratumoral immune microenvironment and survival: the immunoscore]. (2014) (13)
- Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) (2018) (12)
- Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer (2021) (12)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) (2018) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- Trial watch (2013) (12)
- Memory T-cell responses and survival in human cancer: remember to stay alive. (2010) (12)
- The Ultimate Goal of Curative Anti-Cancer Therapies: Inducing an Adaptive Anti-Tumor Immune Response (2011) (11)
- Trial Watch (2012) (11)
- The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy (2020) (11)
- Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study. (2021) (11)
- MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018) (10)
- Trial Watch (2013) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 (2016) (10)
- Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance). (2017) (10)
- Multiverse of immune microenvironment in metastatic colorectal cancer (2020) (9)
- Genomic landscape of tumor-host interactions with differential prognostic and predictive connotations (2019) (9)
- Trial Watch (2004) (9)
- Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). (2018) (9)
- The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival (2021) (9)
- The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions (2020) (9)
- License to kill: microsatellite instability and immune contexture (2021) (9)
- The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers. (2019) (8)
- hSMG-1 is a granzyme B-associated stress-responsive protein kinase (2011) (8)
- Regulation of CD44 isoform expression and CD44-mediated signaling in human dendritic cells. (1997) (8)
- Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives. (2020) (8)
- Usefulness and robustness of Immunoscore for personalized management of cancer patients (2020) (8)
- InflammationMacrophages at Sites of Th1-Mediated Blood Monocytes, Dendritic Cells, and Stat4 Is Expressed in Activated Peripheral (2000) (7)
- No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study (2020) (7)
- Trial Watch: (2013) (7)
- Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR). (2019) (7)
- An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors. (2022) (7)
- Trial watch (2004) (7)
- [Focus on the Immunoscore and its potential clinical implications]. (2017) (7)
- Mise au point sur l’Immunoscore et ses potentielles implications cliniques (2017) (6)
- Ligands and biological activities of soluble Fc gamma receptors. (1995) (6)
- Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer (2021) (6)
- 491P Neoadjuvant nivolumab in early stage colorectal cancer (2020) (6)
- Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH.. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29: 1093-1102 (2009) (6)
- Glucocorticoid-inducible genes that regulate T-cell function. (2002) (5)
- Soluble CD16 in plasma cell dyscrasias. (1999) (5)
- Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (5)
- Trial Watch (2012) (5)
- The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications : Lymphocytic Infiltration in Colorectal Cancer. (2020) (5)
- Immunoscore® as a predictor of response to chemotherapy in stage II and stage III colon cancer (2015) (5)
- Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring (2022) (4)
- Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012 (2013) (4)
- Inhibition of TH1 immune response by glucocorticoids: Dexamethasone inhibits IL-12-induced stat4 phosphorylation in T lymphocytes (2000) (4)
- Evasion before invasion: Pre-cancer immunosurveillance (2021) (4)
- Hafnium Oxide Nanoparticle Activated By Radiation Therapy Generates an Anti-Tumor Immune Response (2018) (4)
- Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. (2021) (4)
- Tissue-resident FOLR2+ macrophages associate with tumor-infiltrating CD8+ T cells and with increased survival of breast cancer patients (2021) (4)
- Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients (2020) (4)
- Metastasis immune-based scores predict patient survival (2020) (3)
- Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR). (2020) (3)
- Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients. (2020) (3)
- High immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced head and neck cancer patients (2019) (3)
- Expand to shield: IL-15 and in situ lymphocytic proliferation (2021) (3)
- Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1 (2019) (3)
- Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response (2022) (3)
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy (2015) (3)
- Characterization of the immune microenvironment of synchronous primary tumor and liver colorectal metastases (2015) (3)
- Immune sunrise: from the immunome to the cancer immune landscape (2022) (3)
- Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis (2019) (3)
- Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma. (2020) (3)
- [Immunology and personalized medicine in oncology]. (2014) (3)
- Quantifying Immunoscore performance – Authors' reply (2018) (2)
- Tumor spread or siege immunity: dissemination to distant metastasis or not (2021) (2)
- Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study (2022) (2)
- Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients. (2017) (2)
- Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). (2017) (2)
- Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer (2020) (2)
- 30: From the immune contexture to the Immunoscore in cancer (2014) (2)
- Abstract LB-016: Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1 (2018) (2)
- D/2 Predictors of Favorable Outcome in Cancer (2011) (2)
- 779 CXCL13-CXCR5 Signaling Is Required for the Anti-Tumor Immune Response in Colorectal Cancer (2014) (2)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (2)
- [Potential immunologic consequences of lymph node dissection in colorectal cancer]. (2008) (2)
- Significant differences in outcome between Immunoscore categories in stage I colon cancer patients. (2019) (2)
- The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life? (2021) (2)
- Intratumoral immune reaction: A novel paradigm for cancer. (2011) (2)
- Trial watch (2004) (1)
- The immune score as a new possible approach for the classification of cancer (2012) (1)
- Soluble Fc gamma receptors: interaction with ligands and biological consequences. (1997) (1)
- 11 Prognostic Markers of the Immune System – Immune Infiltration Into the Tumour (2012) (1)
- Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE). (2018) (1)
- Hafnium oxide nanoparticle activated by radiotherapy to generate an anti-tumor immune response. (2018) (1)
- Abstract CT010: A phase I study of the oncolytic peptide LTX-315 generatesde novoT-cell responses and clinical benefit in patients with advanced sarcoma (2019) (1)
- Preoperative treatment to modify the immune microenvironnement of liver colorectal metastases. (2015) (1)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (1)
- Efficacy of anti-PD1/PD-L1 immunotherapy in non–small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status. (2022) (1)
- Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
- The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 (2020) (1)
- Abstract 4574: Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A proof of concept (2019) (1)
- Abstract 5529: PD-L1 and CD8 IHC dual assessment in NSCLC using the Halioseek® assay: A multicentric study (2018) (1)
- Association of T-cell infiltration assessed in pretherapeutic biopsies (PTB) of patients with locally advanced rectal adenocarcinoma (LARC) with tumor response and relapse after chemoradiotherapy (CRT) and rectal surgery (2017) (1)
- LBA-010Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). (2017) (1)
- Clinical Response in ZUMA‐1, the Pivotal Study of Axicabtagene Ciloleucel (Axi‐Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME): NHL‐168 (2018) (1)
- Primary R 5 HIV-1 Monocytes / Macrophages by Opsonized ( CD 11 b / CD 18 )-Mediated Infection of Soluble CD 16 Inhibits CR 3 (2001) (1)
- Cytokines et cellules dendritiques (1998) (1)
- PP 40 Tumor microenvironment and prognosis in breast carcinoma (2011) (1)
- The consensus Immunoscore adapted to biopsies in patients with locally advanced rectal cancer: Potential clinical significance for a “Watch and Wait” strategy. (2019) (1)
- Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule (2016) (1)
- Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. (2022) (1)
- 79O Clinical performance of Immunoscore® in early colon cancer in the Asian population (2020) (1)
- Upfront FOLFOXIRI Plus Bevacizumab with or Without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (ATEZOTRIBE): A Multicentre, Open-Label, Phase 2, Randomised Controlled Trial by GONO (2022) (1)
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment (2013) (1)
- The impact of cellular senescence and DNA damage on colorectal tumour progression (2013) (1)
- Abstract 1419: Characterization of the evolution of immune response in lung squamous carcinogenesis (2016) (1)
- Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (1)
- molecular mechanisms in tumor-immune cells interaction. (2011) (1)
- SP-0015: The impact of tumour infiltrating lymphocytes on clinical outcome after (chemo)radiotherapy (2017) (0)
- T-cell infiltration on liver colorectal metastases resected after treatment is prognostic (2014) (0)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
- Unravelling the immune contexture of pre-invasive lesions of the lung by multispectral imaging (2018) (0)
- 1984P Tumour infiltrating lymphocytes in early breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in patients undergoing neo-adjuvant chemotherapy (2020) (0)
- Integrating Biomolecular and Clinical Data for Cancer Research: Concepts and Challenges (2012) (0)
- [Not Available]. (2008) (0)
- Characterization of the immunoscore of synchronous resected primary tumor and liver colorectal cancer metastases (2016) (0)
- Abstract IA12: Integrative genomics and immune contexture approach to immuno-oncology (2018) (0)
- 957 Assessment of the spatial distribution and cell-to-cell interactions into the tumor micro-environment, within and between serial slides stained with Brightplex®, a sequential chromogenic multiplex assay (2022) (0)
- Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study (2023) (0)
- 1454 Multiomics and multimodal analysis approach to construct a diffuse large B cell lymphoma atlas of tumor microenvironment for predictive modeling (2022) (0)
- Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (0)
- The immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: Clinical significance for pathological response and survival (2019) (0)
- Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives (2023) (0)
- Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer (2023) (0)
- The role of germline genetics in shaping the tumor immune landscape is largely unknown. Using genotypes from >9,000 (2020) (0)
- Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929. (2020) (0)
- Positive effects of glucocorticoids on T cell function and development by upregulation of interleukin-7 receptor α (2001) (0)
- Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). (2022) (0)
- Prognostic association of FoxP3 regulatory T cells with tumor infiltrating CD8 cytotoxic T cells quantified on resected liver colorectal metastases (LCM). (2015) (0)
- T Cells ( IRF-1 ) Gene Expression in Human NK and IL-12 Induces IFN Regulating Factor-1 Finbloom and (1999) (0)
- MC13-0059 T-cell infiltration (TCI) observed on whole liver colorectal metastases (LCM) resected after preoperative treatment is a prognostic survival factor (2013) (0)
- Homogeneity of pathological response (PR) and histopathological growth pattern (HGP) in resected colorectal liver metastases (CRLM) are associated with favorable survival outcome after surgery. (2022) (0)
- 32P High levels of stromal tumour infiltrating lymphocytes, CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy (2020) (0)
- STAT Activation Syk nor Lck Is Required for IL-2-Mediated Syk Depends on Jak 3 ; However , Neither Interleukin-2 ( IL-2 ) Signaling : Activation of Hierarchy of Protein Tyrosine Kinases in (2000) (0)
- SpatiotemporalDynamicsof Intratumoral ImmuneCells Reveal the Immune Landscape in HumanCancer (2017) (0)
- An in vitro method for prognosis of the course of a cancer, and the outcome of a patient, and means for carrying out this method (2006) (0)
- 57 Assessment of the spatial distribution of B cells subpopulations in the tumor microenvironment and tertiary lymphoid structures by Brightplex®, a sequential chromogenic multiplex assay (2021) (0)
- 41 Assessment of the spatial distribution of CD4+ T cells subpopulations in the tumor microenvironment by Brightplex®, a sequential chromogenic multiplex assay (2021) (0)
- T Lymphocytes Inhibits IL-12-Induced Stat 4 Phosphorylation Glucocorticoids : Dexamethasone Selectively Inhibition of Th 1 Immune Response by Frucht , (2000) (0)
- Characterization of the immune microenvironment and relation to preoperative treatment of synchronous resection of primary tumor and liver colorectal cancer metastases (2017) (0)
- Immunoguiding, the Final Frontier in the Immunotherapy of Cancer (2014) (0)
- Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generatesde novoT-cell responses and clinical benefit in patients with advanced melanoma (2019) (0)
- 46P Tumour infiltrating lymphocytes in breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR in patients receiving neo-adjuvant chemotherapy (2020) (0)
- Results TNBS-Induced Colitis in Resistant and Susceptible Mice (2001) (0)
- P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (2022) (0)
- Trial Watch (2012) (0)
- Trial Watch (2013) (0)
- World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016 (2017) (0)
- [Not Available]. (2008) (0)
- O-17 A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study (2020) (0)
- in vitro method for the prognosis of progression of a cancer and result in a patient and means for carrying out said method (2006) (0)
- Soluble FcγR, a biological perspective (1998) (0)
- Immune contexture and cancer prognosis (88.28) (2009) (0)
- The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions (2020) (0)
- LTX‐315, an oncolytic peptide converts "cold" tumors to "hot" in a majority of patients with advanced cancer: results from an ongoing phase I study (2017) (0)
- Abstract P1-10-14: Focus on tumor infiltrating lymphocytes (TIL’s): High levels of spatially positioned CD3 and CD8 cells and high immunoscores are significantly associated with pathological complete responses in triple-negative breast cancer patients (2020) (0)
- Preoperative treatment modifies the immune microenvironnement of liver colorectal metastase (2015) (0)
- Prognostic histological factors in resected colorectal liver metastasis with preoperative treatment (2017) (0)
- Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer (2023) (0)
- Toward integrative cancer immunotherapy: targeting the tumor microenvironment (2012) (0)
- Favorable tumor immune microenvironment (TME) and robust chimeric antigen receptor (CAR) T-cell expansion may overcome tumor burden (TB) and promote durable efficacy with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). (2021) (0)
- Functional and morphological adrenal changes in TNBS-induced colitis (2000) (0)
- Janus kinases and STAT family transcription factors: their role in the function and development of lymphoid cells (2002) (0)
- Abstract 4624: Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex®, a sequential chromogenic multiplex assay (2023) (0)
- 554PB CELLS (CD20+) ASSOCIATED TO TUMOR INFILTRATING CYTOTOXIC T-CELLS OBSERVED ON RESECTED LIVER COLORECTAL METASTASES (LCM) ARE PROGNOSTIC. (2014) (0)
- In vitro procedure for the prognosis of the progression of a cancer and of the result in a patient and means to carry out said procedure (2006) (0)
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies (2019) (0)
- An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. (2023) (0)
- 2154 Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression (2015) (0)
- Immune evasion before tumour invasion in early lung squamous carcinogenesis (2019) (0)
- Abstract 590: A new standardized CD8 and PD-L1 dual assay (2017) (0)
- 336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies (2022) (0)
- Abstract 5879: Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma (2023) (0)
- Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer (2020) (0)
- Abstract PS6-31: Correlations between tumor-infiltrating lymphocytes, CD3, CD8 cells, and Immunoscore®, with pathological CR and time to progression in triple-negative breast cancer patients undergoing neoadjuvant chemotherapy (2021) (0)
- Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients (2019) (0)
- Abstract CT166: Pretreatment (PreTx) immune cell phenotypes in peripheral blood associated with the tumor immune contexture, product attributes, and durable clinical efficacy in patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) (2021) (0)
- Use of a polypeptide having the activity of soluble human CD16 in the treatment of infection by the HIV virus (1995) (0)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
- Abstract A114: Towards personalized cellular adoptive immunotherapy targeting tumor specific neo-antigens in microsatellite unstable colorectal cancers (2016) (0)
- 743 High levels of stromal tumor infiltrating lymphocytes, CD3, CD8 cells & Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy (2020) (0)
- Immunoregulation and genotype in colorectal cancer (2015) (0)
- Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy (2018) (0)
- S47. Tumour infiltrating lymphocytes - a predictive marker? (2014) (0)
- Caractérisation de l’évolution de la réponse immune dans la carcinogenèse bronchique épidermoïde (2017) (0)
- Etude structurale et fonctionnelle des recepteurs fc gamma solubles de faible affinite (1996) (0)
- 3. Rôle pronostique des lymphocytes T dans les cancers (2020) (0)
- Procédés et kits de criblage de patients atteints d'un cancer (2013) (0)
- Procédés et trousses pour le criblage de patients atteints d'un cancer (2013) (0)
- A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, RAS mutation and Immunoscore (2018) (0)
This paper list is powered by the following services:
Other Resources About Jérôme Galon
What Schools Are Affiliated With Jérôme Galon?
Jérôme Galon is affiliated with the following schools:
